Details of the Drug Combination

General Information of Drug Combination (ID: DCXAJAQ)

• Drug Combination Name: ABIRATERONE + BIO-300
• Indication: Renal cell carcinoma; Status: Investigative [1]
• Component Drugs:
  ABIRATERONE (DM8V75C): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: UO-31
  Zero Interaction Potency (ZIP) Score: 6.87
  Bliss Independence Score: 10.66
  Loewe Additivity Score: 11.22
  LHighest Single Agent (HSA) Score: 14.77

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ABIRATERONE

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[2]

ABIRATERONE Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Steroid 17-alpha-monooxygenase (S17AH)	TTRA5BZ	CP17A_HUMAN	Modulator	[5]

ABIRATERONE Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Decreases Activity	[6]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[7]
Membrane cofactor protein (CD46)	OTQ8NWJD	MCP_HUMAN	Increases Expression	[8]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Response To Substance	[9]

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
Rheumatoid arthritis	FA20	Phase 1	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DCJ378D	MOLT-4	Investigative	[1]
Chronic myelogenous leukemia	DCY4M3E	K-562	Investigative	[1]
Clear cell renal cell carcinoma	DCY6Z1X	TK-10	Investigative	[1]
Glioma	DCDBPMK	SF-539	Investigative	[1]
Plasma cell myeloma	DC4LKRS	RPMI-8226	Investigative	[1]
Breast adenocarcinoma	DCGMH4G	MDA-MB-468	Investigative	[10]
Carcinoma	DCVER8D	RXF 393	Investigative	[10]
Carcinoma	DCZ7F0H	MCF7	Investigative	[10]
Colon carcinoma	DCW9574	KM12	Investigative	[10]
Adenocarcinoma	DCOJUXG	OVCAR3	Investigative	[11]
Adenocarcinoma	DCUQOL1	NCIH23	Investigative	[11]
Adenocarcinoma	DCEUISK	A549	Investigative	[11]
Adenocarcinoma	DC4ROT5	SW-620	Investigative	[11]
Adenocarcinoma	DCH4V7Z	HCT116	Investigative	[11]
Adenocarcinoma	DCX2JO5	HCC-2998	Investigative	[11]
Adenocarcinoma	DCDLZLP	HCT-15	Investigative	[11]
Adenocarcinoma	DCPKYQB	HT29	Investigative	[11]
Amelanotic melanoma	DCBGA2Q	M14	Investigative	[11]
Amelanotic melanoma	DCBPDWP	MDA-MB-435	Investigative	[11]
Cutaneous melanoma	DCJDGFG	SK-MEL-28	Investigative	[11]
High grade ovarian serous adenocarcinoma	DCHJHEU	OVCAR-5	Investigative	[11]
High grade ovarian serous adenocarcinoma	DCT80CC	OVCAR-8	Investigative	[11]
Lung adenocarcinoma	DCCMCPF	MDA-MB-231	Investigative	[11]
Lung adenocarcinoma	DCSDS32	HOP-62	Investigative	[11]
Lung adenocarcinoma	DC72CT0	NCI-H522	Investigative	[11]
Melanoma	DCHOEY1	MALME-3M	Investigative	[11]
Pleural epithelioid mesothelioma	DCWA9WR	NCI-H226	Investigative	[11]
Prostate carcinoma	DCFFW46	PC-3	Investigative	[11]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
• [3] Clinical pipeline report, company report or official report of Humanetics.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [6] A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
• [7] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [8] Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6.
• [9] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [10] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [11] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.